<DOC>
	<DOCNO>NCT01561027</DOCNO>
	<brief_summary>The study randomize , double blind , cross-over study evaluate safety efficacy CNV1014802 subject neuropathic pain lumbosacral radiculopathy .</brief_summary>
	<brief_title>Crossover Study CNV1014802 Subjects With Neuropathic Pain From Lumbosacral Radiculopathy</brief_title>
	<detailed_description>The study consist two treatment period 22 day randomize CNV1014802 350mg placebo administer twice daily . In addition , single blind placebo administer two week run-in , two week wash-out period two treatment period , one week run-out phase .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Radiculopathy</mesh_term>
	<criteria>Male female age 18 65 year , diagnosis neuropathic pain due lumbosacral radiculopathy ( LSR ) . Female subject must nonchild bear potential agree use approve form contraception Body weight &lt; 50 kg men &lt; 45 kg woman . Capable give write informed consent . Approved concomitant medication must stable least 4 week prior day 1 . Average baseline daily pain score neuropathic pain due LSR 11point numerical rating scale 4 great . Subjects unable reliably delineate ass pain anatomical location/distribution . Subjects lumbar canal stenosis pain low limb occur solely walk rest . Subjects cause neuropathic pain LSR . Subjects receive nerve block and/or steroid injection neuropathic pain within 4 week prior day 1 . Subjects indicate surgical treatment lumbosacral radiculopathy . A positive prestudy drug screen . A positive history HIV . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . History liver disease within last 6 month , exception know Gilbert 's disease . History excessive regular alcohol consumption within 6 month study . Subjects history risk seizures history epilepsy , head injury related neurological disorder Subjects history uncontrolled poorly control hypertension , systolic BP frequently exceed 160mmHg and/or diastolic BP frequently exceed 100mmHg , subject BP great equal 160mmHg systolic and/or great equal 100mmHg diastolic screen repeated measurement History presence significant cardiovascular , gastrointestinal , renal disease condition know interfere absorption , distribution , metabolism , excretion drug . Subjects condition know affect cardiac conduction personal familial history Brugada syndrome Pregnant females lactate female . History presence clinically significant abnormality vital sign / ECG / laboratory test medical psychiatric condition , , opinion Investigator may interfere study procedure compromise subject safety . History suicidal ideation and/or suicide attempt clinical evidence recent major depression . Subjects unable maintain medication treatment neuropathic pain stable dose study . Unable refrain excessive use sedative . Unable comply prohibit concomitant medication restriction detail protocol . This include limited sodium channel blocker drug adversely interact monoamine oxidaseB inhibitor : MAOI 's , antidepressant , opioids sympathomimetic agent . Unable stop remain abstained nonpharmacological treatment neuropathic pain study . History hypersensitivity CNV1014802 . The subject participate clinical trial receive investigational product within 5 halflives twice duration biological effect investigational product ( whichever longer ) prior start study . Exposure four new chemical entity within 12 month prior first dose day . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>